Back to Test Catalogue

Alzheimer’s Disease Biomarkers Panel, CSF

Test ID: ALZD CSF

Test

Method

Electrochemiluminescent immunoassays

Method Description

Elecsys® AD CSF assay

Platform

Roche cobas©

Report Includes

BetaAmyloid42 (ABeta42); Phosphorylated Tau 181 (pTau); Total Tau (Tau)

Specimens

CSF
Sample must be collected in a Sarstedt FB CSF Collection tube 63.614.625 (blue cap) tube.
These tubes can be ordered from In-Common Laboratories, using the Client Supply Request form.

Clinical Utility

Please refer to Roche Press Release.

Test Location

London Health Sciences Centre, 339 Windermere Road, London ON N6A 5A5

Test Version

27-Oct-2023

Specimen

Specimens

CSF
Sample must be collected in a Sarstedt FB CSF Collection tube 63.614.625 (blue cap) tube.
These tubes can be ordered from In-Common Laboratories, using the Client Supply Request form.

Collection Containers

Sarstedt 63.614.625 (blue cap) tube

Sample Volume

2.5 mL

Minimum Volume

1.5 mL

Collection & Handling

Collection Instructions

Specimens for Alzheimer’s Disease Biomarkers must be collected and handled as described in this downloadable document: Collection & Handling Instructions.
Note: CSF must be collected into the Sarstedt 63.614.625 (blue cap) tube.
β-amyloid peptides will adhere to plastics such as polystyrene. Failure to follow the recommended collection protocol may result in a falsely low Aβ42 result and contribute to an incorrect diagnosis of Alzheimer’s disease.

Handling Information

Specimens for Alzheimer’s Disease Biomarkers must be collected and handled as described in this downloadable document: Collection & Handling Instructions.

Stability

Ambient 12 hours
Refrigerated 14 days
Frozen 60 days

Rejection Criteria

Specimen Not collected as described

Test Version

27-Oct-2023

Performance / Interpretation

Method

Electrochemiluminescent immunoassays

Method Description

Elecsys® AD CSF assay

Platform

Roche cobas©

Turnaround Time

11 days

Results

Name Units Reference Range Conversion Factor
BetaAmyloid42 (ABeta42) pg/mL
  • > 1030.0
Phosphorylated Tau 181 (pTau) pg/mL
  • ≤ 27.00
Total Tau (Tau) pg/mL
  • ≤ 300
pTau:ABeta42 Ratio
  • ≤ 0.0230
Compared to CSF concentrations of ABeta42, pTau, and Tau individually, the pTau/ABeta42 ratio has been shown to better correlate with Alzheimer's disease-related pathologic change as measured by amyloid PET scan.
Please note that improper specimen collection or handling technique may falsely decrease ABeta42 and increase the pTau/ABeta42 ratio.
Discrepancies in interpretation of the pTau/ABeta42 ratio compared to CSF concentrations of ABeta42, pTau, and/or Tau individually may relate to improper specimen collection/handling, inter-individual variation in beta-amyloid CSF concentration, a disorder related to CSF dynamics, and/or elevation in pTau due to a non-Alzheimer's disease-related pathologic change.
Clinical correlation is required. For patients with values near cutoffs, interpretation in the context of clinical history is particularly important.

Test Location

London Health Sciences Centre, 339 Windermere Road, London ON N6A 5A5

Test Version

27-Oct-2023

Interface / Setup

HL7 Interface Codes

Order Code Result Codes Units
ALZD CSF 65228BetaAmyloid42 (ABeta42),CSF pg/mL
65229Phosphorylated Tau 181 (pTau),CSF pg/mL
65230Total Tau (Tau),CSF pg/mL
65231Alzheimer Interp (ABeta42,pTau,Tau),CSF
65232pTau:ABeta42 Ratio,CSF
65233Alzheimer Interp (pTau:ABeta42Ratio),CSF
65234General Alzheimer's Comment,CSF

Test Version

27-Oct-2023